The artificial intelligence company Deep 6 A.I. in Pasadena has announced significant network growth, meant to speed up clinical trials for medical and life science researchers, along with the appointment of two new company executives.
Chris Brubaker has joined the company as chief marketing and customer officer, while Talha F. Basit has been named chief technology officer, according to Deep 6 CEO Wout Brusselaers.
A major challenge to running clinical studies is finding appropriate patients, Brubaker said. It’s a large contributor to the reason it can take years to bring new treatments to market.
“An average clinical trial has around 15 criteria that a patient needs to meet to join a clinical trial and about 20 to 25 exclusion criteria, things that they can’t have to be included in a clinical trial,” he said.
Traditionally, those running trials had to rely on searching so-called “structured” data, which is information recorded in the form of medical billing codes, according to Brubaker. “And 80% or 90% of the data in healthcare is actually unstructured. It’s the medical notes that doctors write. It’s the comments that radiologists put in the notes when they view an X-ray or an MRI.”
Deep 6 employs A.I. to read through all of the available information, including handwritten notes, to provide researchers with the best information possible.
“We basically, at this point, built the largest network of unstructured patient data in the U.S., and possibly the world,” Brusselaers said.
The network of clients and participants now includes dozens of leading research institutions, including 6 NCI-designation comprehensive cancer centers, 30,000 healthcare providers, 30 million patients and thousands of active trials, according to Deep 6.
“Because when we partner with these organizations, we go very deep, we amass a lot of data that typical traditional software doesn’t know how to analyze,” Brusselaers added.
More information on Deep 6 A.I. is available on the company’s website at deep6.ai.